Lenalidomide Capsule
Product Images NDC 0574-1402

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 0574-1402). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Padagis Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg Label (10mg Label)

Lenalidomide Capsules 10 mg capsule label for oral use. The label includes a warning about potential birth defects, states the package contains 28 capsules, and is labeled by Padagis US LLC. It features storage instructions, a QR code, and batch details with lot number, expiration date, serial number, and GTIN. Manufactured by QILU Pharmaceutical Co., Ltd. in China.*

FDA Label Image

15mg Label (15mg Label)

Lenalidomide Capsules 15 mg oral dosage form, packaged by Padagis US LLC. The label indicates 21 capsules in the container and includes a warning about potential human birth defects. It provides storage instructions and notes manufacturing by QILU Pharmaceutical Co., Ltd in China. The label also displays a barcode and sections for lot number, expiration date, serial number, and GTIN.*

FDA Label Image

2.5 Label (2 5mg Label)

Packaging label for Lenalidomide Capsules 2.5 mg by Padagis US LLC. The label states the product is prescription only and contains 28 capsules. It includes a warning about potential human birth defects, storage instructions, and manufacturer information (QILU Pharmaceutical Co., Ltd., China). A barcode and lot, expiration, serial number, and GTIN fields are also present.*

FDA Label Image

20mg Label (20mg Label)

Lenalidomide Capsules 20 mg package label displaying the product name, dosage strength, and quantity (21 capsules). It includes a boxed warning about potential human birth defects and storage instructions. The labeler is Padagis US LLC, and manufacturing information for QILU Pharmaceutical Co., Ltd. in China is also shown, along with a barcode and a QR code with lot, expiration, and serial number fields.*

FDA Label Image

25mg Label (25mg Label)

Label for Lenalidomide 25 mg capsules by Padagis US LLC. The label includes the product name, strength, quantity of 21 capsules, a warning about potential human birth defects, storage instructions, and manufacturer information. It also shows a barcode and a section for lot, expiration date, serial number, and GTIN.*

FDA Label Image

5mg Label (5mg Label)

Lenalidomide Capsules 5 mg oral dosage form in a package containing 28 capsules. The label includes a warning for potential human birth defects, storage instructions, and mentions the labeler as Padagis US LLC. It also indicates manufacture by QILU Pharmaceutical Co., Ltd., China, and features a QR code and lot, expiration, serial number, and GTIN fields.*

FDA Label Image

Figure 1 (Figure01)

A Kaplan-Meier survival curve chart showing progression-free survival probability (%) over time in months for three groups: Rd Continuous, Rd18, and MPT. The chart includes a table of the number of subjects at risk over time and hazard ratio (HR) data with confidence intervals and a logrank p-value for statistical comparison.*

FDA Label Image

Figure02 (Figure02)

A Kaplan-Meier survival curve chart displaying overall survival probability over time (months) for three groups: Rd Continuous, Rd18, and MPT. The y-axis shows survival probability percentage, and the x-axis shows time in months up to 72. The chart includes hazard ratios comparing the groups and a table of the number of subjects at risk and events for each group at different time points.*

FDA Label Image

Figure03 (Figure03)

Kaplan-Meier plot showing progression-free survival over time in months comparing lenalidomide (line 1) versus placebo (line 2). The y-axis represents progression-free survival probability, and the x-axis represents time in months. The graph includes hazard ratio and confidence intervals, and a table below shows the number of subjects at risk over time for each group.*

FDA Label Image

Figure04 (Figure04)

A Kaplan-Meier survival curve graph comparing progression-free survival (months) between Lenalidomide and Placebo groups. The Y-axis denotes survival probability, and the X-axis denotes time in months. The Lenalidomide group shows higher survival probability over time compared to Placebo. The number of subjects at risk decreases over time with accompanying event counts.*

FDA Label Image

Figure05 (Figure05)

A Kaplan-Meier survival curve comparing the proportion of subjects over time to progression (months) between two groups: Lenalidomide/Dex and Placebo/Dex. The graph shows time to progression with hazard ratio and statistical data included, illustrating comparative progression-free survival.*

FDA Label Image

Figure06 (Figure06)

A Kaplan-Meier curve chart depicting the proportion of subjects over time to progression (months) for two groups: Lenalidomide/Dex and Placebo/Dex. The chart shows a higher proportion of subjects without progression over time in the Lenalidomide/Dex group compared to the Placebo/Dex group, with statistical annotations including hazard ratio and p-value.*

FDA Label Image

Structure (Structure)

Chemical structure of lenalidomide showing its molecular arrangement including a substituted phthalimide and glutarimide moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.